Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Ivan Borbath et al.|The Lancet Oncology|2012Cited by 550
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationTerence Hall, Giovanni Abbadessa|PLoS ONE|2016Cited by 84